Boston Scientific’s stock has had a rough ride in 2026. BSX touched a 52-week low of $60.54 on April 21, with the stock currently trading around $60.43–$60.99 — a far cry from its 52-week high of $109.50.
Boston Scientific Corporation, BSX
That’s a drop of about 36% year-to-date, erasing billions from the company’s $90.6 billion market cap.
Stifel analyst Rick Wise lowered his price target on BSX to $85 from $90 ahead of first-quarter 2026 earnings, which are due on April 22, 2026. He kept his Buy rating in place.
The cut was driven by monthly electrophysiology (EP) hospital-purchasing data Stifel uses to get a read on the quarter before results come in.
January data was about 92% reported, February around 85%, and March at roughly 60% — giving a partial but meaningful picture of EP revenue trends.
Based on that data, Stifel believes BSX’s Q1 US EP consensus revenue target of around $587 million is “within the band of achievability.” That’s not a ringing endorsement, but it’s not a warning bell either.
Stifel leaned on a comparison with Johnson & Johnson and Abbott Laboratories, using that same EP purchasing database to cross-check projected vs. actual revenues. The firm previously flagged potential downside risk to US EP consensus revenues ahead of the prior quarter using a similar method.
Despite the bearish price action, the analyst community hasn’t abandoned ship. Truist Securities kept its Buy rating while lowering its target to $90 from $92. The firm expects the cardiovascular segment to grow 8.5% to 9% in the upcoming report.
RBC Capital reiterated an Outperform rating with a $115 price target after speaking directly with BSX executives about growth prospects.
UBS held its Buy rating and $105 target following the CHAMPION-AF trial results for the Watchman heart implant. The trial hit all primary and secondary endpoints — a positive outcome that UBS says reduces headline risk.
There’s a wrinkle though. The Watchman device showed a slightly higher ischemic stroke rate compared to non-vitamin K antagonist oral anticoagulants (NOACs), which disappointed some investors.
Piper Sandler kept its Overweight rating after feedback from a high-volume electrophysiologist who expects Watchman usage to increase despite the stroke data.
InvestingPro has flagged BSX as one of its most undervalued stocks, placing its Fair Value at $76.66 — roughly 27% above where it’s currently trading.
Revenue growth has remained strong, with BSX posting nearly 20% growth over the last twelve months. That’s not a struggling business on paper — it’s a stock under pressure.
All eyes now turn to April 22, when BSX reports Q1 2026 earnings. That report will be the first real test of whether EP revenue held up as Stifel’s data suggests it might.
The post Boston Scientific (BSX) Stock Drops 36% as Analysts Revise Targets Ahead of Earnings appeared first on CoinCentral.
